Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RZLT 
Rezolute Inc (RZLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RZLT (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.11
1 Year Target Price $13.11
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 158.89% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 565.47M USD | Price to earnings Ratio - | 1Y Target Price 13.11 |
Price to earnings Ratio - | 1Y Target Price 13.11 | ||
Volume (30-day avg) 10 | Beta 0.19 | 52 Weeks Range 2.21 - 6.64 | Updated Date 08/15/2025 |
52 Weeks Range 2.21 - 6.64 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.85% | Return on Equity (TTM) -95.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 480356902 | Price to Sales(TTM) - |
Enterprise Value 480356902 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.01 | Shares Outstanding 86996000 | Shares Floating 76708263 |
Shares Outstanding 86996000 | Shares Floating 76708263 | ||
Percent Insiders 9.65 | Percent Institutions 89.51 |
Upturn AI SWOT
Rezolute Inc
Company Overview
History and Background
Rezolute, Inc. is a late-stage biopharmaceutical company dedicated to developing novel therapies for metabolic diseases. Founded to address unmet needs in rare metabolic disorders, Rezolute focuses on innovative treatments with the potential to improve patient outcomes. The company's evolution has been marked by clinical trials, regulatory milestones, and strategic partnerships to advance its pipeline.
Core Business Areas
- Rare Metabolic Disease Therapeutics: Developing and commercializing novel therapies for rare metabolic diseases, with a focus on congenital hyperinsulinism (CHI).
Leadership and Structure
The leadership team comprises experienced pharmaceutical executives and scientists. The organizational structure includes research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- RZ358: RZ358 is a late-stage investigational monoclonal antibody being developed for the treatment of congenital hyperinsulinism (CHI). Market share data is not yet available as the product is not yet approved. Competitors include Diazoxide and surgical options; future competitors may emerge from other companies developing therapies for CHI. Revenue from this product is $0 until product approval.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. The market for rare metabolic diseases is a growing segment, driven by increased awareness and advancements in diagnostic tools.
Positioning
Rezolute is positioned as a specialized biopharmaceutical company focused on rare metabolic diseases, with a lead candidate targeting a significant unmet need in CHI. The company's competitive advantage lies in its innovative approach and the potential of RZ358 to improve patient outcomes.
Total Addressable Market (TAM)
The estimated TAM for CHI is approximately $500 million to $1 billion globally. Rezolute is positioning itself to capture a significant portion of this market with RZ358, pending regulatory approval and successful commercialization.
Upturn SWOT Analysis
Strengths
- Strong focus on rare metabolic diseases
- RZ358 is in late-stage clinical development
- Experienced management team
- Potential to address a significant unmet medical need
Weaknesses
- Reliance on a single lead product (RZ358)
- High risk associated with clinical trials and regulatory approval
- Limited commercial infrastructure
- Dependence on raising capital to fund operations
Opportunities
- Potential expansion of RZ358 to other indications
- Strategic partnerships with larger pharmaceutical companies
- Increasing awareness and diagnosis of rare metabolic diseases
- Favorable regulatory environment for orphan drugs
Threats
- Failure of RZ358 in clinical trials
- Competition from existing or new therapies
- Regulatory delays or rejection
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- ADMP
- DRIO
Competitive Landscape
Rezolute competes with other pharmaceutical and biotechnology companies developing therapies for rare metabolic diseases. Its competitive advantage lies in its innovative approach and the potential of RZ358 to address a significant unmet need.
Growth Trajectory and Initiatives
Historical Growth: Rezolute's historical growth is characterized by progress in clinical trials and strategic partnerships. The company's growth is dependent on the successful development and commercialization of RZ358.
Future Projections: Future growth projections are based on analyst estimates and company guidance regarding clinical trial timelines and regulatory milestones. These projections are subject to significant uncertainty.
Recent Initiatives: Recent initiatives include enrolling patients in phase 3 clinical trials for RZ358, presenting clinical trial data at scientific conferences, and strengthening its intellectual property portfolio.
Summary
Rezolute Inc. is a high-risk, high-reward biopharmaceutical company focused on rare metabolic diseases. Its success hinges on the successful development and commercialization of RZ358. The company's limited product pipeline and reliance on future capital raises pose significant challenges. However, the potential of RZ358 to address a significant unmet need presents a compelling growth opportunity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (e.g., 10-K, 10-Q)
- Company press releases
- Analyst reports
- Company website
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and projections are subject to change. The AI-based rating is based on available data and should be interpreted with caution.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rezolute Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-05-01 | Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Mr. Nevan Charles Elam J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 68 | Website https://www.rezolutebio.com |
Full time employees 68 | Website https://www.rezolutebio.com | ||
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.